Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

DraftKings (NASDAQ: DKNG) is forecasting robust growth in revenue and profitability in 2025. Read More: Earn up to $845 cash ...

In the last one year, the stock has gained 113 per cent and in the last one month the stock has been moving in a range of Rs ...

Entergy has strong growth potential but appears overvalued. See why ETR stock’s favorable regulatory environment and dividend ...

Chandan Taparia has recommended three stocks to buy today – Infosys, Bank of Baroda, and Power Finance Corporation ...

Micron Technology, Inc. MU, a leader in the semiconductor sector, has shown resilience amid turbulent market conditions. The ...

The brokerage reiterated its 'Buy' rating on the stock with a revised target price of Rs 2,235. When comparing Hyundai Motor ...

Hindalco shares: Hindalco reported a 123% year-on-year (YoY) rise in standalone net profit, amounting to Rs 1,891 crore.

According to analysts, this subdued sentiment is likely influenced by the company's continued losses, despite steady revenue ...

Shares of FMCG player Britannia Industries tumbled 4% to an intraday low of Rs 5,220 on the BSE; Should you invest?

Choosing a Stock Market Strategy That Fits Your Portfolio Objectives and Skills Peter Gratton, M.A.P.P., Ph.D., is a New ...